
LXEO Stock Forecast & Price Target
LXEO Analyst Ratings
Bulls say
Lexeo Therapeutics is attractive because LX2006 targets the underlying frataxin deficiency driving lethal FA cardiomyopathy, a setting with no approved therapy for the cardiac manifestations and an estimated ~5,000 U.S. FA patients. The bullish case is strengthened by Phase 1/2 evidence showing LVMI reductions in all 6 patients with abnormal baseline LVMI, including ~18% at 6 months and ~28% in the mid- and high-dose cohorts, while Monte Carlo work suggests >99% of simulated SUNRISE-FA 2 trials reach the ≥15% LVMI threshold. Beyond LX2006, the 4Q26 LX2020 update, the 2H27 pivotal readout, and a modeled ~30%/~10% market value assigned to FA and PKP2-ACM respectively imply meaningful upside from a pipeline still underappreciated by the Street.
Bears say
Lexeo Therapeutics is viewed negatively because its AAV-based gene therapies remain exposed to major safety and efficacy uncertainty, including serious adverse events, immune responses, off-target effects, and the fact that only early data are available for its corrective effect. The company also faces stringent FDA scrutiny that could require additional studies or longer, more capital-intensive pivotal trials, which may force future equity issuance at less attractive valuations and strain its financing profile. Even if approved, commercial adoption could be limited by payer resistance, high treatment costs, and competition from more convenient small-molecule alternatives, while multiple programs may dilute the market potential of its pipeline.
This aggregate rating is based on analysts' research of Lexeo Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LXEO Analyst Forecast & Price Prediction
Start investing in LXEO
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Lexeo Therapeutics Inc (LXEO) Forecast
LXEO Analyst Forecast & Price Prediction
Start investing in LXEO
Order type
Buy in
Order amount
Est. shares
0 shares